Richard James Whitley

Dr. Richard J. Whitley, also known as Rich, M.D., Ph.D., serves as an Advisor of Vaxart, Inc. Dr. Whitley serves as Divisional Director of Pediatric Infectious Diseases, Vice Chairman of Department of Pediatrics, Senior Scientist of Department of Gene Therapy, Senior Scientist of Cancer Research and Training Center, Associate Director for Clinical Studies of Center for AIDS Research, Director of Center for Biodefense and Emerging Infections at The University of Alabama at Birmingham. He manages a large clinical trials program funded by the NIH. He serves as Scientific & Strategic Advisor at Janus Pharmaceuticals, Inc. He serves as an Advisor to the NIH and FDA. He serves as an Advisor to the Infectious Diseases Society of America. He serves as a Director of Gilead Palo Alto, Inc. He serves as a Member of Advisory Bodies at the National Institute of Health and the U.S. Food and Drug Administration. He has been an Independent Director of Gilead Sciences, Inc. since July 2008 and Gilead Palo Alto, Inc since 2008. He serves as a Member of Scientific Advisory Board at 3-V Biosciences, Inc. He serves as a Director of Primus Pharmaceuticals, Inc. He serves as a Member of Influenza Advisory Board at Adamas Pharmaceuticals, Inc. He has been a Member of Clinical Advisory Board at Ansun Biopharma, Inc. since April 2009. He serves as a Member of Scientific Advisory Board at Juvaris BioTherapeutics, Inc., Nurel Therapeutics, Inc., Vaxin Inc., Aviron & Integrated Nano-Technologies LLC, Microbiotix, Inc., Apath, LLC and ImQuest Pharmaceuticals, Inc. He has been a Member of Scientific & Medical Advisory Board at Inhibitex, Inc. since November 2007. He serves as a Member of Advisory Board at Intelligent Medical Devices Inc. He served as a Member of Scientific Advisory Board at ContraVir Pharmaceuticals, Inc. until August 17, 2016. He served as a Member of Scientific Advisory Board and Clinical Advisory Board at Achillion Pharmaceuticals, Inc. Dr. Whitley served as a Member of the Overseas Advisory Board of aRigen Pharmaceuticals, Inc. He served as an Independent Health Policy Advisory Board at Gilead Sciences, Inc. He served as a Member of Scientific Advisory Board at Gilead Sciences, Inc. from 2003 to 2008. He served as a Member of Scientific & Medical Advisory Board at Mertiva AB (publ) since 2006. He served as a Member of Scientific & Medical Advisory Board at Diamyd Medical AB since 2006. Dr. Whitley served as a Director of FermaVir Pharmaceuticals, L.L.C. and Venus Beauty Supply Inc. since August 16, 2005. He served as a Member of Scientific Advisory Board at Arrow Therapeutics Ltd., Genelabs Technologies Inc., Chimerix, Inc. and Epiphany Biosciences, Inc. He served as a Member of the Scientific Advisory Council at MediGene AG. Dr. Whitley's other research interest is in the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy and engineering of herpes simplex virus for gene therapy. He served as President of the International Society of Antiviral Research. Dr. Whitley is an Editor of Antiviral Research and is a Member of the Editorial Boards of the Jounal of Infectious Diseases, Sexually Transmitted Diseases, Reviews in Medical Virology, Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Infectious Diseases Watch for Pediatricians, Seminars in Pediatric Infectious Diseases, Gene Therapy and Medscape Infectious Disease. He has won several awards for his work. Dr. Whitley has been elected to the Infectious Diseases Society of America, Fellow, American Society of Microbiology, American Society of Clinical Investigation and Association of American Physicians. He is a Professor of Pediatrics, Microbiology and Medicine at the University of Alabama in Birmingham and holds the Loeb Eminent Scholar Chair in Pediatrics. Dr. Whitley graduated from George Washington University School of Medicine with an MD and from Duke University with a BS in Chemistry. He holds B.A in chemistry from Duke University.